EN

ENZYCHEM LIFESCIENCES CORPORATION

Develops small molecule therapeutics for cancer, inflammation, and respiratory diseases.

183490 | KO

Overview

Corporate Details

ISIN(s):
KR7183490002
LEI:
Country:
South Korea
Address:
충청북도 제천시 바이오밸리로 59, 제천시

Description

Enzychem Lifesciences Corporation is a biopharmaceutical company that develops novel small molecule therapeutics. The company's research targets fundamental pathways in inflammation to address significant unmet medical needs for patients with cancer, inflammatory diseases, and severe respiratory conditions. Its leading drug candidate, EC-18 (Mosedipimod), is a first-in-class oral small molecule derived from Sika deer antler. The clinical pipeline for EC-18 includes indications such as chemoradiation-induced oral mucositis (CRIOM), chemotherapy-induced neutropenia (CIN), acute radiation syndrome (ARS), and non-alcoholic steatohepatitis (NASH). The company also develops and manufactures Active Pharmaceutical Ingredients (APIs).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-18 00:00
조회공시요구(현저한시황변동)에대한답변(중요정보없음)
Korean 5.0 KB
2025-12-17 00:00
조회공시요구(현저한시황변동)
Korean 3.5 KB
2025-08-20 00:00
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 33.2 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.9 MB
2025-06-10 00:00
신탁계약해지결과보고서
Korean 21.5 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean 1.7 MB
2025-04-21 00:00
주식등의대량보유상황보고서(일반)
Korean 93.4 KB
2025-04-08 00:00
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-26 00:00
정기주주총회결과
Korean 26.9 KB
2025-03-24 00:00
주식등의대량보유상황보고서(일반)
Korean 95.3 KB
2025-03-18 00:00
감사보고서제출
Korean 26.3 KB
2025-03-18 00:00
사업보고서 (2024.12)
Korean 2.5 MB
2025-03-12 00:00
신탁계약에의한취득상황보고서
Korean 49.5 KB
2025-03-07 00:00
주주총회소집공고
Korean 264.6 KB
2025-03-07 00:00
의결권대리행사권유참고서류
Korean 216.5 KB

Automate Your Workflow. Get a real-time feed of all ENZYCHEM LIFESCIENCES CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ENZYCHEM LIFESCIENCES CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ENZYCHEM LIFESCIENCES CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chong Kun Dang Pharmaceutical Corp. Logo
Develops and manufactures drugs for systemic anti-infectives and metabolic diseases.
South Korea
185750
CHOONG ANG VACCINE LABORATORY Logo
Develops and manufactures vaccines, pharmaceuticals, and feed additives for animals.
South Korea
072020
CHOSA Oncology AB Logo
Develops diagnostics and therapeutics for platinum-based chemotherapy.
Sweden
CHOSA
CHUGAI PHARMACEUTICAL CO., LTD. Logo
A research-driven pharmaceutical company developing innovative medical products.
Japan
4519
CHUKYOIYAKUHIN CO.,LTD. Logo
Offers health products and pharmaceuticals via a direct-to-home placement service.
Japan
4558
Cidara Therapeutics, Inc. Logo
Develops targeted immunotherapies and anti-infectives for serious diseases.
United States of America
CDTX
Cinclus Pharma Holding AB Logo
Clinical-stage pharma company developing a PCAB for gastric acid-related diseases.
Sweden
CINPHA
Cingulate Inc. Logo
A clinical-stage biopharma firm developing treatments for ADHD and anxiety.
United States of America
CING
CITIUS ONCOLOGY, INC. Logo
Biopharmaceutical company developing and commercializing targeted oncology therapies.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
A late-stage biopharmaceutical company developing and commercializing critical care products.
United States of America
CTXR

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.